PharmaTimes

INSPIRE tips the balance for Seretide in COPD mortality

Seretide/Advair is GSK’s best-selling drug, and the line was extended in 2003 when the European Union approved the higher-dose 500 Accuhaler for the symptomatic treatment of severe COPD, i.e., ...
pharmaphorum

Use generic alternatives to Seretide and save millions, advises NICE

The generic drug, montelukast should be offered to people ahead of combination inhalers such as GlaxoSmithKline's Seretide, in a bid to save the NHS millions of pounds, according to draft guidance ...
Reuters

Glaxo's Seretide approved for wider use in Europe

LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...
FiercePharma

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
pharmaphorum

Boehringer's Spiolto tops Seretide in head-to-head COPD trial

Boehringer Ingelheim's recently-approved Spiolto is more effective than GlaxoSmithKline's Seretide/Advair in improving lung function in patients with chronic obstructive pulmonary disease (COPD), ...